CClinicalTrials.gg
Sign In
CompletedNCT04004390PPS and IGIVUpdated Mar 10, 2020

Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin

An observational study in Post-Poliomyélitis Syndrom, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
17
Ages
30 Years and older
Sex
All
01

Study summary

Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital

Read the detailed description

Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the department of MPR on the criteria of judgment, then the patient is admitted in a service of neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service for post-treatment evaluation.

Collection of data retrospectively.

02

Conditions studied

  • Post-Poliomyélitis Syndrom

Keywords

  • Pre- and post-therapeutic evaluation carried out
  • Data transcribed in the computerized patient file
  • post-poliomyelitis syndrome
  • Intravenous immunoglobulins
  • walking test
  • isokinetics
03

In context

Poliomyelitis

222 studies on the registry are indexed under Poliomyelitis; 11 are open to participants now.

This study's enrollment of 17 is below the median of 450 across 19 observational studies indexed under Poliomyelitis.

Browse Poliomyelitis studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

15 men and 11 women with Diagnosis of PPS

Inclusion criteria

  • Diagnosis of PPS
  • Pre- and post-therapeutic evaluation carried out
  • Data transcribed in the computerized patient file

Exclusion criteria

Exclusion Criteria:

  • No walking patient
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
17 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Muscular strength

    Muscular strength with isokinetic

    Time frame: 5 months

Secondary outcomes

  1. Walking perimeter

    Walking perimeter with walking test (6 minutes)

    Time frame: 5 months

07

Study locations

1 site
  • Uh Montpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04004390
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Jun 28, 2019
Primary completion
Dec 1, 2019
Completion
Dec 30, 2019
Last update
Mar 10, 2020

Study contacts

MOIZIARD Vincent, intern
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Poliomyelitis→

Other studies from this sponsor

University Hospital, Montpellier

Start the discussion